VTN and neoplasm: Moreover, the treatment significantly reduced expression levels of EGFRvIII, integrin αvβ3, VTN, as well as the cellular distributions of integrin β3, αv in non-necrotic area of the tumor mass in vivo in EGFRvIII-xenografts (Figure 7C and Supplementary Figure S2C).